6533b7d0fe1ef96bd125b016
RESEARCH PRODUCT
The Spectrum of Ocular Manifestations in Patients with Waldenström's Macroglobulinemia.
Tero KiveläRosanna DammaccoWalter LischAlberto MavilioEvangelos TerposRoberto RiaEfstathios KastritisDario SistoGiovanni AlessioAngelo VaccaFranco Dammaccosubject
Intraocular pressuremedicine.medical_specialtyVisual acuitygenetic structuresmedicine.medical_treatment03 medical and health sciences0302 clinical medicineCentral retinal vein occlusionOphthalmologymedicineImmunology and AllergyPapilledemabusiness.industryMacroglobulinemiamedicine.diseaseeye diseases3. Good healthOphthalmology030220 oncology & carcinogenesis030221 ophthalmology & optometryRituximabPlasmapheresismedicine.symptombusinessmedicine.drugRetinopathydescription
Purpose: To investigate the ocular manifestations in 91 Waldenstrom's macroglobulinemia (WM) patients.Methods: Retrospective, cross-sectional, observational analysis.Results: Ocular impairments, detected in 19 patients, included flame-shaped hemorrhages, venous sausaging, papilledema, macular detachments, or central retinal vein occlusion in 16 patients; paraproteinemic keratopathy in 2; and a CANOMAD syndrome in 1. Best-corrected visual acuity was ≥0.5 logMAR units in 11 of 38 eyes. Intraocular pressure was increased in seven eyes. Genetic analysis in seven patients showed a mutation in the MYD88 gene in six patients and a nonsense mutation in the CXCR4 gene in five patients. Plasmapheresis followed by chemotherapy with or without the addition of rituximab resulted in improvement or normalization of the ophthalmological findings in 15 patients.Conclusion: The ocular manifestations of WM are protean and potentially sight threatening. Recent advances in genomic profiling and chemotherapy have remarkably improved the hematological and ophthalmological outcomes of these patients.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2021-07-16 | Ocular immunology and inflammation |